An AI algorithm that incorporates scoring of coronary inflammation based on coronary CT angiography (CCTA) may enhance long-term cardiovascular risk stratification beyond conventional risk factor and imaging assessments, even in patients without obstructive CAD.

Offering access to over 110 AI applications, the enterprise imaging platform enables radiologists to test, deploy and monitor the use of AI technologies.

Additional carcinoma in the ipsilateral breast was detected on preoperative MRI exams in 24 out of 102 women prior to lumpectomy and mastectomy procedures, according to new study findings presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The AI-powered Heuron ICH software reportedly has an 86 percent sensitivity rate for diagnosing intracranial hemorrhage on computed tomography (CT) scans.

An AI model that includes extracted radiomic features from CT scans more than doubled the sensitivity rate for preoperative prediction of lung cancer recurrence in comparison to traditional TNM staging, according to study findings to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

In comparison to pure solid nodules in patients with non-small cell lung cancer (NSCLC), nodules with a minor ground glass opacity component were associated with over a 38 percent higher rate of recurrence-free survival.

In addition to detecting missed lung nodules on X-rays, the AI-powered Qure.ai lung cancer continuum platform reportedly automates lung nodule measurement on CT scans and facilitates multimodality reporting.

The second-generation version of the VUZE System reportedly offers expanded functionality and incorporation of varied sources of 3D imaging data, including cone-beam CT scans obtained in the OR.

One deep learning model had a 72.4 percent accuracy rate for differentiating between benign and malignant solid pulmonary nodules on non-contrast CT while another deep learning model demonstrated an 87.1 percent AUC for differentiating benign and inflammatory findings.

Developed by an extended prostate cancer working group of the European Society of Urogenital Radiology (ESUR), the updated PI-QUAL scoring system emphasizes a simplified scale of image parameters that applies to prostate MRI scans with and without intravenous contrast use.

Emphasizing restriction spectrum imaging (RSI), the recently launched prostate MRI software OnQ Prostate may enhance PI-RADS assessments and workflow efficiency.

While standard approaches to imaging may be elusive amid shifting protocols from different facilities and different specialties, there is a balancing act of flexible accommodation and pushing back against unreasonable requests.

Catch up on the most-well viewed radiology content in May 2024.

Catch up on the top radiology content of the past week.

PSMA PET/CT demonstrated an 83 percent pooled detection rate for primary or metastatic renal cell carcinoma (RCC), and an 87 percent detection rate for restaging of metastatic or recurrent RCC, according to a nine-study meta-analysis.

Catch up on the top AI-related news and research in radiology over the past month.

For patients with no history of coronary artery disease (CAD), new research shows the use of CT-derived fractional flow reserve (FFR-CT) guided revascularizations after elective vascular surgery reduced myocardial infarction and all-cause death by 20 percent in comparison to standard care.

Image quality, sharpness, and contrast with AI-based denoising were significantly enhanced for neck CT in comparison to conventional CT image reconstruction at 100 percent and 50 percent mAs, according to newly published research.

In a study of over 2,000 women with dense breasts and average breast cancer risk, abbreviated MRI (AB-MR) demonstrated an 18.9 per 1000 cancer detection rate (CDR) in baseline exams, and all cancers detected with baseline or subsequent AB/MR exams were stage 0 or 1.

New prospective research examining the utility of 18F-PSMA-1007 PET/CT revealed comparable sensitivity to mpMRI for detecting clinically significant prostate cancer and a 17 percent higher specificity rate.